Abstract Number: 1759 • ACR Convergence 2021
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…Abstract Number: 1784 • ACR Convergence 2021
Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry
Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention…Abstract Number: 1857 • ACR Convergence 2021
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…Abstract Number: 0046 • ACR Convergence 2021
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…Abstract Number: 0061 • ACR Convergence 2021
Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms in the psoriatic arthritis (PsA) joint. This is evidenced by the fact that…Abstract Number: 0356 • ACR Convergence 2021
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
Background/Purpose: Skin disease affects >80% of lupus patients and has been linked to lupus nephritis (LN) flares. We recently found that skin inflammation caused by…Abstract Number: 0513 • ACR Convergence 2021
Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood
Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…Abstract Number: 0545 • ACR Convergence 2021
SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells
Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…Abstract Number: 0546 • ACR Convergence 2021
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…Abstract Number: 0555 • ACR Convergence 2021
Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data
Background/Purpose: Omic analyses of systemic sclerosis (SSc) skin biopsy datasets identified distinct sets of patients that respond differently to treatment. The goal of this study…Abstract Number: 0557 • ACR Convergence 2021
The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…Abstract Number: L09 • ACR Convergence 2020
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…Abstract Number: 1610 • ACR Convergence 2020
Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India
Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »